Literature DB >> 19567413

Global investments in TB control: economic benefits.

Ramanan Laxminarayan1, Eili Y Klein, Sarah Darley, Olusoji Adeyi.   

Abstract

The Global Plan to Stop TB calls for significant financial resources to meet the Millennium Development Goals for tuberculosis. However, it is unclear whether the economic benefits of TB control exceed the costs. Using an epidemiological model, we find that the economic benefits of the Global Plan relative to sustained DOTS (a commonly used treatment method) were unambiguously greater than the incremental costs in all nine high-burden countries in Africa and in Afghanistan, Pakistan, and Russia. Benefit-cost ratios of sustaining DOTS at current levels relative to having no DOTS exceeded 1 in all twenty-two high-burden, TB-endemic countries and sub-Saharan Africa.

Entities:  

Mesh:

Year:  2009        PMID: 19567413     DOI: 10.1377/hlthaff.28.4.w730

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  14 in total

1.  Optimizing reactive responses to outbreaks of immunizing infections: balancing case management and vaccination.

Authors:  Petra Klepac; Ottar N Bjørnstad; C Jessica E Metcalf; Bryan T Grenfell
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

2.  Bridging implementation, knowledge, and ambition gaps to eliminate tuberculosis in the United States and globally.

Authors:  Kenneth G Castro; Philip LoBue
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

Review 3.  How can mathematical models advance tuberculosis control in high HIV prevalence settings?

Authors:  R M G J Houben; D W Dowdy; A Vassall; T Cohen; M P Nicol; R M Granich; J E Shea; P Eckhoff; C Dye; M E Kimerling; R G White
Journal:  Int J Tuberc Lung Dis       Date:  2014-05       Impact factor: 2.373

4.  Bioeconomic analysis of child-targeted subsidies for artemisinin combination therapies: a cost-effectiveness analysis.

Authors:  Eili Y Klein; David L Smith; Justin M Cohen; Ramanan Laxminarayan
Journal:  J R Soc Interface       Date:  2015-06-06       Impact factor: 4.118

5.  Testing and treating the missing millions with tuberculosis.

Authors:  Madhukar Pai; Puneet Dewan
Journal:  PLoS Med       Date:  2015-03-24       Impact factor: 11.069

6.  Surveying the Knowledge and Practices of Health Professionals in China, India, Iran, and Mexico on Treating Tuberculosis.

Authors:  Steven J Hoffman; G Emmanuel Guindon; John N Lavis; Harkanwal Randhawa; Francisco Becerra-Posada; Masoumeh Dejman; Katayoun Falahat; Hossein Malek-Afzali; Parasurama Ramachandran; Guang Shi; C A K Yesudian
Journal:  Am J Trop Med Hyg       Date:  2016-02-22       Impact factor: 2.345

7.  Trend analysis and longitudinal clustering of tuberculosis mortality in Asian and North African countries: Results from the global burden of disease 2017 study.

Authors:  Masoud Salehi; Nasim Vahabi; Hassan Pirhoseini; Farid Zayeri
Journal:  Med J Islam Repub Iran       Date:  2021-04-08

8.  Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination.

Authors:  Arindam Nandi; Anita Shet
Journal:  Hum Vaccin Immunother       Date:  2020-01-24       Impact factor: 3.452

9.  Measuring and improving the quality of tuberculosis care: A framework and implications from the Lancet Global Health Commission.

Authors:  Catherine Arsenault; Sanam Roder-DeWan; Margaret E Kruk
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2019-08

Review 10.  Beyond UHC: monitoring health and social protection coverage in the context of tuberculosis care and prevention.

Authors:  Knut Lönnroth; Philippe Glaziou; Diana Weil; Katherine Floyd; Mukund Uplekar; Mario Raviglione
Journal:  PLoS Med       Date:  2014-09-22       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.